Here's Why Replimune Stock Skyrockets Nearly 223% in 3 Months Zacks Equity Research Aug 10, 2026 REPL's RP1 secures FDA approval for advanced melanoma, easing regulatory uncertainty. The company expands its oncolytic immunotherapy pipeline.